Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

NCT03063242 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03063242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03063242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sargramostim to Reverse Myeloid Dendritic Cell Deficiency
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Terminated
Start date
February 23, 2017
Completion date
September 17, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney diseases, kidney transplant